Amber company logo

Rewriting the Rules of Medicine

The Safe,


abstract gene image

& Precise Future

for Genetic Medicine

About Us

Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits to reach previously undruggable patient populations.
The current paradigm in genetic medicine relies on developing independent therapies for each separate mutation in the patient population.
Founded by pioneers in the CRISPR field from leading institutions for gene editing research, the company is developing a first-of-its-kind RNA writing platform capable of editing thousands of diverse mutations across patients with a single product.
Amber gemAmber gem


Amber gemAmber gem


Amber gemAmber gem

Larger Edits

Our Values

Biologically Inspired

Biology is the most sophisticated and specialized form of technology accessible to our species. We humbly study biological systems, learn from them, and put them back together in new ways to build technologies to improve health.

Designed with Artisanship

We blend complex science with biological design. Our work is made possible by approaching biology through an artisan lens, allowing us to explore new avenues, discover novel connections, and advance meaningful paradigms.

Driven by Impact

We believe in a future where life’s most complex diseases are treated at scale. Gene therapies should be safe, easy, precise, and affordable. We work backwards from impact, building out a new frontier of genetic medicine.

Meet The Team

Supported by a vibrant and diverse group of scientists and industry experts. United by a shared vision of enhancing the therapeutic toolkit.

Awilda Rosario

Senior Bioarchitect

David Schaffer, PhD


David Yao, PhD

Bioarchitect II

Dylan Cable, PhD

ML Researcher

Federico Mingozzi


Fei Chen, PhD


Gene Yeo, PhD


Jacob Borrajo, PhD

CEO and Co-Founder

Jim Griffin, PhD

Senior Computational Biologist

Jory Bell

Board Member

Kaisle Hill

Biodesigner III

Kamyab Javanmardi, PhD

VP of Platform

Makala Keys

HR Business Partner

Melissa Jurica, PhD


Nicholas Henninger

Biodesigner III

Nicholas Reynolds

Biodesigner III

Patty Biezonski, PhD

VP of Development

Paul Blainey, PhD


Puloma Sen

Biodesigner III

Sam DeMario, PhD

Bioarchitect I

Susan St Martin

Bioarchitect I

Tou Lee

Lab Manager

Vineeta Agarwala, MD, PhD

Board Member

Made Possible With